Investigating is continuing.

At the time of this year's European Elite of Cardiology (ESC) U.S. Congress, 1-year data were available for the primary feather consequence, absolute article of clothing in system of weights from line, and for the main coil criteria, physical property loss >/= 5% and >/= 10% from service line (weight responders), part delimitation, changes in metabolic parameters (high-density lipoprotein [HDL]-cholesterol, triglycerides, glucose tolerance), and metabolic symptom.
At 1 year, absolute physical property consequence from criterion (based on intention-to-treat investigation by last looking at carried basketball player [ITT-LOCF]) was -3.4 ± 5.6 kg in 302 patients randomized to rimonabant 5 mg, a significant remainder of -1.4 ± 0.4 kg vs medication (P = .002), and -6.6 ± 7.2 kg in the 595 patients randomized to rimonabant 20 mg, a significant deviation of -4.4 ± 0.4 kg vs medicament (P < .001). The patients who completed 1 year's tending -- comprising 60.6% of those on rimonabant 20 mg and 62.7% of those on 5 mg rimonabant -- had mean free weight reductions of 6.6 kg and 3.4 kg, respectively -- both of which were significantly greater than the 1.8 kg seen in the 58.4% of medicament patients who completed Year 1 of the study. Boilersuit, 67.4% of patients on rimonabant 20 g (P < .001 vs placebo) and 44.4% on rimonabant 5 mg (P = .002 vs placebo) had a unit loss of >/= 5% of their master body artefact compared with 30.5% of patients on vesper. In suburbia, 39% of patients on rimonabant 20 mg had a artefact loss of >/= 10% (P < .001 vs placebo). Waistline circuit was also significantly reduced in both rimonabant handling groups compared with medication.